Expansive Clinical Study Finds Improved Outcomes in Heart Transplant Patients Utilizing Paragonix Advanced Organ Preservation
Paragonix Technologies, Inc ., a leading organ transplant company, announced today the publication of groundbreaking research from a clinical study on patient outcomes following heart transplant surgery.
- Paragonix Technologies, Inc ., a leading organ transplant company, announced today the publication of groundbreaking research from a clinical study on patient outcomes following heart transplant surgery.
- Published in The American Society for Artificial Internal Organs (ASAIO), the study utilized data collected by the GUARDIAN-Heart Registry, the world’s largest clinical database dedicated to donor heart preservation, to analyze post-transplant outcomes and the impact on organ preservation methods on transplant patient health.
- The US multi-center analysis of GUARDIAN Registry data included 569 adult patients who received heart transplants between October 2015 and January 2022 .
- “Particularly, in the post-allocation change era, with increasing travel distances and ischemic times, advanced hypothermic organ preservation is an important resource for transplant centers to consider.”
“The ongoing results of the GUARDIAN-Heart Registry have shown advanced preservation to be a potential game-changer for heart transplant patients.